Neurodiclovit

Quick links to important sections

Neurodiclovit

Selected form

Method of action: Analgesic, Anti-Inflammatory

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neurodiclovit

Quick Facts

Property Description
Active Ingredients Diclofenac, Thiamine (Vitamin B₁), Pyridoxine (Vitamin B₆), Cyanocobalamin (Vitamin B₁₂)
Form Oral Solid Dosage (Hard Capsule)
Pharmacological Class Non-Steroidal Anti-inflammatory Drug (NSAID) and B Vitamin Complex
Primary Type Fixed-Dose Combination (FDC)
Origin Synthetic and Semi-synthetic

What Type of Medicine is Neurodiclovit? (Identity & Classification)

Neurodiclovit is a medicinal product defined as a fixed-dose combination (FDC), which is typically manufactured as a hard capsule for oral route of administration. It integrates active ingredients from two separate pharmacological classes: the Non-Steroidal Anti-inflammatory Drug (NSAID) component and a complex of essential B Group Vitamins. This FDC structure represents a strategic approach to pain management, where the combination is intended to provide enhanced pain-relieving efficacy compared to Diclofenac used alone. The medicine is used for managing conditions characterized by pain and inflammation, such as those affecting the spine, and is typically available as a prescription-only item.


What is the Composition of Neurodiclovit? (Ingredients & Origin)

The formulation includes four key active components: Diclofenac (as the sodium salt), a synthetic phenylacetic acid derivative, alongside the B Group Vitamins: Thiamine (Vitamin B₁), Pyridoxine (Vitamin B₆), and Cyanocobalamin (Vitamin B₁₂). The Diclofenac component functions as the highly effective NSAID, while the B Vitamins provide neurotropic support essential for nerve cell function. Neurodiclovit's unique differentiating factor is the specific inclusion of all three neurotropic B vitamins in a single capsule, which is positioned to target both the inflammatory source of pain and the metabolic integrity of the nerve tissue.


What is the General Purpose of Combining these Ingredients? (High-Level Utility)

The general purpose of Neurodiclovit is to provide comprehensive relief for pain associated with inflammatory conditions, such as acute low back pain, by leveraging a synergistic analgesic effect. The product is designed to execute the rapid anti-inflammatory effect of the NSAID concurrently with the known neurotropic action of the B Vitamins. This dual strategy is recognized as beneficial for mitigating inflammation and supporting nervous system metabolism, making it a targeted option for conditions where nerve involvement is suspected alongside significant inflammation.

What side effects are possible with Neurodiclovit?

Possible side effects and safety information

The safety profile of Neurodiclovit, a fixed-dose combination containing an NSAID (Diclofenac) and B Vitamins, is primarily defined by the risks associated with the Diclofenac component. Adverse effects are officially classified by System-Organ Class and frequency according to regulatory standards (Common, Uncommon, Rare, Very Rare).


Documented Adverse Reactions

Commonly documented effects include those affecting the Gastrointestinal System, such as nausea, vomiting, diarrhea, dyspepsia, and abdominal pain, along with Nervous System effects like headache and dizziness. These are among the most frequently listed adverse reactions in regulatory documents.


Serious Regulatory Safety Notes

The product carries official warnings for serious cardiovascular thrombotic events, including the potential for myocardial infarction and stroke, which may be fatal. This risk is typically associated with higher doses and longer duration of exposure. Additionally, the label documents the potential for serious gastrointestinal events, such as bleeding, ulceration, and perforation, which can occur at any time during treatment and may also be fatal.

Very rare, severe reactions such as Stevens-Johnson syndrome and fulminant hepatitis are also listed in regulatory prescribing information.


Population-Specific Constraints

Official documents indicate that older adults are at a higher risk for serious gastrointestinal adverse events. The medicine is contraindicated in patients with severe established heart failure or those in the third trimester of pregnancy. A specific risk documented for the B vitamin component is peripheral neuropathy, associated with the long-term use and high dosage of the Pyridoxine component.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived from regulatory safety data for Diclofenac, the primary active component of Neurodiclovit. This information is not intended as medical advice but reflects documented overdose risks and required emergency actions.

Overdose can present with symptoms primarily affecting the Gastrointestinal (GI) and Central Nervous System (CNS).

Documented Overdose Manifestations Severe Outcomes Requiring Urgent Care
Epigastric pain, nausea, vomiting, diarrhea Gastrointestinal bleeding, ulceration, or perforation
Headache, dizziness, drowsiness, confusion Acute renal failure, liver damage, convulsions, or coma

Required Emergency Action

Immediate medical help must be sought right away upon suspected Neurodiclovit overdose. There is no specific antidote for Diclofenac overdose. Treatment is generally symptomatic and supportive, focusing on managing severe complications and stabilizing the patient.

Official procedural instructions may include considering the administration of activated charcoal and providing specific supportive measures for manifestations such as hypotension or seizures. Monitoring of vital signs and key laboratory values is necessary due to the risk of serious complications, particularly acute kidney or liver injury. Patients with a history of GI issues are at increased risk for severe GI events during overdose.

Therapeutic Uses of Neurodiclovit

The medication is commonly used to provide symptomatic relief across therapeutic domains involving distressing symptoms and inflammation, particularly in the musculoskeletal system. The combination of ingredients may assist with easing the overall symptom load and supports general well-being during symptomatic phases. This combination is relevant in contexts involving heightened systemic burden in specific conditions, notably those associated with degenerative changes.

It is commonly used across conditions presenting with acute episodes where symptoms cluster into patterns requiring supportive management, such as lumbago, acute low back pain, painful vertebral syndromes, and lumbosacral radiculopathy (sciatica). This supportive use is relevant in clinical settings that involve acute or unstable symptom patterns when symptoms create noticeable physiological strain.

The formulation is considered relevant for easing symptoms of mixed pain syndromes, where pain is related to both inflammatory or irritative states and symptoms of increased neurological or muscular activity, such as in certain forms of neuralgia. The application of this product is designed to assist patients in coping more steadily with difficult nerve-related manifestations and temporary functional strain.


Quick Fact: Relief for Mixed Musculoskeletal Pain

Symptom Domain Clinical Context Patient Benefit
Acute Inflammatory Pain Painful vertebral syndromes, acute low back pain Supports the patient during difficult episodes by easing distress.
Nerve-Related Discomfort Lumbosacral radiculopathy, neuralgia Assists with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

Who can and cannot use Neurodiclovit?

The medicine's eligibility profile is based on official government labeling, primarily constrained by the Diclofenac (NSAID) component.

Contraindicated Populations (Must Not Use):

  • History of GI Bleeding/Ulcers or NSAID Hypersensitivity (including aspirin-sensitive asthma) [Source 1.1].
  • Severe Organ Impairment: Patients with severe renal failure or severe hepatic failure [Source 1.2].
  • Cardiovascular Disease: Those with established Ischaemic Heart Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Class II-IV) [Source 3.7].
  • Late-Stage Pregnancy: Contraindicated in the last trimester (from about 30 weeks gestation) due to fetal risks [Source 4.1].
  • Post-Surgical Setting: Prohibited immediately before or after Coronary Artery Bypass Graft (CABG) surgery [Source 1.2].

Restricted and Age-Related Use:

Population Regulatory Status
Pediatric (Under 18) Not Established/Not Recommended for use; safety is unproven [Source 1.1].
Older Adults Use requires caution; the lowest effective dose for the shortest duration is advised [Source 1.2].
Breastfeeding Conditional Use; potential benefits must be weighed against unknown infant risks [Source 4.1].

Conditional Use: Patients with mild-to-moderate organ impairment or cardiovascular risk factors must be treated with caution and close monitoring, as specified in regulatory documents [Source 3.5].

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Neurodiclovit is primarily determined by its Diclofenac component, a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory information structures interactions into categories based on resulting clinical constraints.

Pharmacodynamic (PD) Interactions

Co-administration with other medicines that affect hemostasis can increase the risk of bleeding. These include other systemic NSAIDs, corticosteroids, anticoagulants (such as warfarin), and antiplatelet agents (including low-dose aspirin, SSRIs, and SNRIs). Regulatory documents require that concurrent use with another systemic NSAID or analgesic doses of aspirin be generally avoided. Furthermore, Diclofenac may diminish the desired effects of diuretics and certain antihypertensive agents (e.g., ACE inhibitors and Angiotensin II Receptor Blockers/ARBs), necessitating close monitoring of patient blood pressure and fluid balance.

Pharmacokinetic (PK) Interactions

Diclofenac can increase the plasma concentrations of certain co-administered drugs by reducing their clearance. This risk applies to medicines such as Digoxin, Lithium, and Methotrexate, which may require careful monitoring of serum levels. Similarly, co-administration with strong inhibitors of the CYP2C9 enzyme (such as Voriconazole) can significantly increase the exposure to Diclofenac itself. The concurrent use of Ciclosporin or Tacrolimus with Diclofenac requires caution due to an increased risk of kidney toxicity.

Mechanism of Action

Neurodiclovit employs a dual-mechanism approach by simultaneously targeting the biochemical source of inflammation and influencing the nervous system's metabolic regulation, which exhibits a synergistic relationship at the level of the physiological response.

Interference with Inflammatory Mediator Synthesis

The Diclofenac component acts as an inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). This molecular action interrupts the Arachidonic Acid Cascade, suppressing the synthesis of Prostaglandin E2 ( PGE2) and related mediators. This reduces the peripheral sensitization of nociceptors and contributes to the attenuation of the inflammatory response.

Maintenance and Regulation of Neuronal Metabolic Integrity

The B Vitamin complex ( B1, B6, B12) exerts a distinct neurotropic mechanism by functioning as essential coenzymes in key metabolic pathways. These vitamins are critical for neuronal energy production ( ATP), the biosynthesis of inhibitory and regulatory neurotransmitters, and the maintenance of the myelin sheath. This action influences the regulatory state of targeted neural pathways, affecting nerve cell metabolic integrity and signal transmission.

Synergistic Interaction and Antinociceptive Modulation

The combination exhibits a synergistic relationship at the physiological level in pain states where inflammatory or neuropathic components are present. Diclofenac provides rapid peripheral blockade, while the B vitamins contribute to functional and metabolic regulation of nerve tissue and enhanced descending pain system modulation. This combined strategy leads to a physiological modulation that influences the drug's antinociceptive activity.

Dosage and Administration Information

Official Administration Guidelines for Neurodiclovit

Neurodiclovit is an oral medication, typically supplied as a film-coated tablet or capsule. These instructions outline the method and rules for administration as defined in governmental regulatory documents.


Administration Protocol

Administration Element Official Rule
Route Oral (swallowable tablet/capsule).
Dosing Schedule One tablet/capsule daily or one capsule three times daily (dependent on specific formulation and physician's direction). Use the lowest effective dose for the shortest duration possible.
Timing To be taken after meals (postprandial) to help minimize potential gastrointestinal discomfort.
Preparation The tablet/capsule must be swallowed whole (unchewed) with a small amount of liquid (e.g., water).

Specific Use Constraints

  • Age-Group Use: The medication is generally intended for adults. Some official documents advise that use in children, particularly those under 14 years of age, is typically not recommended or must be determined by a physician due to the diclofenac component.
  • Duration Limit: The high-dosage B-vitamin component in this combination product requires avoiding treatment for periods longer than four consecutive weeks to mitigate the risk of specific neurological symptoms, such as peripheral neuropathy.
  • Missed Dose: Official instructions commonly advise that if a dose is missed, the patient should skip the missed dose and continue with the regular schedule. Do not double the dose to catch up.

The full procedure involves simply taking the prescribed number of whole tablets/capsules post-meal with water, strictly adhering to the frequency and duration limits set by the prescribing doctor and regulatory warnings.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neurodiclovit

Evidence for Use in Acute Pain Syndromes of the Spine

This section summarizes the structure of Randomized Controlled Trials (RCTs) and Systematic Reviews that have investigated the combination of diclofenac and B vitamins for acute conditions like low back pain and painful vertebral syndromes. The content outlines the main endpoints (e.g., pain scores, functional measures) that were examined in these key studies.

The combination of diclofenac and B vitamins was evaluated in research exploring conditions characterized by outcomes capturing phases of heightened symptom activity, specifically acute low back pain and painful vertebral syndromes. The most relevant research includes short-term comparative trials where patients presenting with these acute issues were evaluated in a research setting. These trials examined outcomes related to physical discomfort and daily functioning or activity level.

Findings describe patterns observed in the studies where the combination was associated with a shorter time to the study-defined remission endpoint compared to the single ingredient alone. Research also indicates that some trials monitored whether patients required reduced amounts of the NSAID component over the treatment period. While multiple RCTs have been conducted, the evidence remains predominantly focused on the acute phase of these conditions. The research typically observes responses over defined time intervals of a week or two; consequently, long-term effects are not fully established.

Research on Long-Term Outcomes and Follow-up Duration

This area summarizes the duration of observation in the most relevant clinical trials and outlines what is known about the durability of the reported measurements after the initial acute treatment phase. This includes a description of the available data regarding extended observation periods, recurrence, or functional maintenance over extended periods.

For the primary indication of acute spinal pain, the key research was observed in studies where the follow-up durations were limited. Most of the evidence for the combination was evaluated in trials that lasted less than 14 days, which is typical when researching episodes of heightened symptom activity. What remains uncertain is the course of outcomes reflecting daily functioning over the long term. There is limited information for long-term outcomes regarding the sustained effects of the combination on addressing future symptom patterns or measurements of daily functioning after the treatment period ends.

Main Uncertainties and Research Gaps

Key research gaps include the limited information for long-term outcomes, as most trials are designed for the short-term, acute phase of conditions characterized by fluctuating or episodic manifestations. The follow-up durations were limited in most comparative studies. Additionally, subgroup findings are uncertain due to data for certain groups remain insufficient. Future research is ongoing and may help to clarify uncertainties and add to the body of research for this fixed-dose combination.

Frequently Asked Questions (FAQ)

Common questions about Neurodiclovit (FAQ)


Q: Is Neurodiclovit the same as regular Diclofenac?

A: No, Neurodiclovit is a fixed-dose combination product that contains Diclofenac (an NSAID) plus three B-group vitamins: Thiamine ( B1), Pyridoxine ( B6), and Cyanocobalamin ( B12). Regular Diclofenac contains only the Nonsteroidal Anti-inflammatory Drug (NSAID) component.


Q: What makes Neurodiclovit different from just taking Diclofenac and B vitamins separately?

A: The combination is authorized based on clinical evidence that suggests it is cited as producing a synergistic effect in specific painful conditions. Studies have examined the combination's performance against the single NSAID ingredient, and some studies examined a shorter time to symptom remission with the fixed combination.


Q: Are the B vitamins in Neurodiclovit (B1, B6, B12) a high dose?

A: Yes, the formulation contains the B vitamins at doses considered high, particularly Pyridoxine ( B6). Regulatory warnings indicate that the product should not be used for longer than four consecutive weeks to mitigate the specific risk of nerve damage (peripheral neuropathy) associated with the high dose of B6 over extended periods.


Q: Why is Diclofenac combined with B vitamins in this medication?

A: The ingredients are combined to provide a dual strategy for pain management. Diclofenac provides a rapid anti-inflammatory effect, while the B vitamins ( B1, B6, B12) contribute to the metabolic support of nerve tissue. This combination is cited in regulatory documents as producing a synergistic pain-relieving effect in certain inflammatory conditions.


Q: How does the B12 component in Neurodiclovit contribute to its action?

A: Cyanocobalamin ( B12), along with the other B vitamins, functions as a coenzyme in metabolic processes critical for the nervous system. These B vitamins support neuronal energy production, the synthesis of neurotransmitters, and the maintenance of the myelin sheath, thus influencing nerve cell metabolic integrity.


Q: How long does it typically take for Neurodiclovit to start working?

A: Since the product contains Diclofenac, which is a rapidly absorbed NSAID, the pain-relieving effects are typically observed relatively soon after administration. Effects are typically observed shortly after administration, consistent with the pharmacological characteristics of the NSAID component.


Q: Is the effect of Neurodiclovit long-lasting or short-term?

A: The duration of effect is determined by the Diclofenac component. Based on its pharmacological profile, it is characterized as having a short-to-intermediate duration of effect.


Q: What are the most common side effects people report with Neurodiclovit?

A: Official regulatory documents describe effects on the Gastrointestinal System, such as nausea, vomiting, diarrhea, indigestion, and abdominal pain, as commonly documented. Additionally, nervous system effects like headache and dizziness are also frequently reported.


Q: Is it common to feel stomach discomfort when taking Neurodiclovit?

A: Yes. Regulatory documents list various gastrointestinal disturbances, including abdominal pain, nausea, and dyspepsia (indigestion), as commonly documented undesirable effects of the Diclofenac component. Official instructions specify that the capsules should be taken after meals to help minimize this potential discomfort.


Q: Can Neurodiclovit be used for general back pain?

A: The product is officially indicated for the treatment of inflammatory pain and painful conditions of the spine, such as acute low back pain and painful vertebral syndromes. The authorized indications typically focus on specific, acute inflammatory conditions rather than general or chronic pain issues.


Q: Can Neurodiclovit be used for muscle spasms?

A: The product is indicated for painful vertebral syndromes and inflammatory pain, conditions which frequently involve secondary muscle tension or spasm. However, its primary classification is an NSAID and B vitamin combination.


Q: Can Neurodiclovit be used for nerve pain specifically?

A: In some regulatory regions, the product or similar fixed combinations are specifically indicated for certain forms of neuralgia (nerve pain) and polyneuropathies (nerve damage) alongside inflammatory conditions. This is due to the inclusion of the neurotropic B vitamins.


Q: What does the available research say about the effectiveness of Neurodiclovit?

A: Clinical trials for the combination product indicate that it was associated with a shorter time to remission in acute painful vertebral syndromes compared to using diclofenac alone. Most available research evidence is focused on short-term, acute phases of these conditions, and some trials observed a shorter time to symptom remission with the fixed combination.


Q: Is there evidence to support the use of Neurodiclovit for chronic conditions?

A: The product is typically authorized for short-term treatment of acute conditions. Official instructions advise using the lowest effective dose for the shortest duration possible, and regulatory warnings advise against use for longer than four consecutive weeks due to the B vitamin component.


Q: What are the signs that Neurodiclovit might not be working for a user?

A: Regulatory documents state that the patient's symptomatic relief and response to therapy should be re-evaluated periodically. If symptoms of pain or inflammation are not satisfactorily reduced, a re-evaluation of the treatment's therapeutic goal is typically warranted, as stated in regulatory guidelines.


Q: What is the difference in safety between Neurodiclovit and other NSAIDs?

A: The safety profile is dominated by the Diclofenac component and is therefore similar to other NSAIDs, including serious risks of cardiovascular thrombotic events and GI bleeding. The specific difference is the added, serious risk of peripheral neuropathy associated with the long-term, high-dose B6 component, which requires strict treatment duration limits.


Q: Is there a risk of dependency or addiction with Neurodiclovit?

A: No. The active ingredients are Diclofenac (an NSAID) and B vitamins. This product does not belong to the class of medications that are associated with physical dependency or addiction.


Q: Does Neurodiclovit contain steroids?

A: No. The main active ingredient is Diclofenac, which is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). NSAIDs work through a mechanism different from that of corticosteroids (steroids).


Q: Is Neurodiclovit the same drug as Neurofen?

A: No. Neurodiclovit contains Diclofenac and B vitamins. Nurofen (a brand name) contains Ibuprofen, which is a different Non-Steroidal Anti-inflammatory Drug (NSAID) with a different chemical structure.


Q: How quickly do the B vitamin levels build up when taking Neurodiclovit?

A: The B vitamins are rapidly absorbed. However, due to the high doses, regulatory warnings advise against use exceeding four consecutive weeks because of the risk of accumulation of the B6 component over time.


Q: Is it safe to take Neurodiclovit if I am already taking a multivitamin?

A: Official documents caution that the product already contains high doses of B vitamins ( B1, B6, B12). The long-term use of the B6 component is associated with the risk of peripheral neuropathy. Adding B vitamin supplements while using this product would increase the overall intake, which should be considered in light of the regulatory warnings about high doses.


Q: Do the B vitamins in Neurodiclovit interact with hormonal birth control?

A: Regulatory documentation for this product does not typically list a direct interaction with hormonal contraceptives. However, if a patient experiences severe gastrointestinal side effects (like vomiting or severe diarrhea), absorption of oral contraceptives could potentially be reduced.


Q: Are there any food or drinks that interact with Neurodiclovit?

A: Official instructions specify that the capsules should be taken after meals to minimize gastrointestinal discomfort. Furthermore, regulatory documents for NSAIDs often advise caution regarding the concurrent consumption of alcohol due to an increased risk of gastrointestinal bleeding.


Q: Is it normal to see a change in urine color while taking Neurodiclovit?

A: While not always explicitly listed as an adverse effect, the B vitamin components (especially B12) can cause urine to become brighter yellow or orange in color. This is typically harmless and results from the body excreting excess vitamins.


Q: Does Neurodiclovit affect blood sugar levels?

A: Some official documents list diabetes mellitus as a significant risk factor requiring caution with the diclofenac component. Although the product does not universally carry this specific warning, the general NSAID profile is associated with a potential for changes in blood sugar levels.


Q: Does Neurodiclovit cause drowsiness or affect driving?

A: The Diclofenac component is associated with central nervous system side effects such as dizziness and headache. If a patient experiences these effects, official guidelines advise against driving or operating machinery.


Q: Can Neurodiclovit cause changes in mood?

A: Official documents categorize effects on the nervous system, listing dizziness and headache as common. Less common or rare effects sometimes listed for diclofenac-containing products include psychiatric disturbances such as confusion, disorientation, insomnia, and irritability.


Q: Are there generic versions of Neurodiclovit available?

A: Products containing the same fixed combination of Diclofenac and B1, B6, and B12 are manufactured and marketed by various companies in different countries. Whether an identical, officially classified 'generic' product is available depends on the specific country's regulatory status and market.


Q: What is the shelf life of Neurodiclovit?

A: The official regulatory documents (e.g., the Summary of Product Characteristics or Patient Information Leaflet) specify the precise shelf life (e.g., 2 years or 3 years) as determined during the marketing authorization process. This date is printed on the packaging and is valid only if the stated storage conditions are met.


Q: Are there any restrictions on physical activity while using Neurodiclovit?

A: Regulatory documents do not place general restrictions on physical activity. However, if the patient experiences common side effects like dizziness or headache, which affect co-ordination or judgment, it may be necessary to avoid activities requiring full attention, including demanding physical activity, as specified in regulatory guidelines.

How should Neurodiclovit be stored and disposed of?

Storage Conditions and Requirements

The official storage conditions for Neurodiclovit capsules mandate that the medicine must be stored at a temperature below 25^circC. To maintain the stability of the active components, the product must be protected from light and moisture.

The capsules must be kept in the original package (blister and outer carton) and, as a mandatory safety requirement, must be kept out of the sight and reach of children.

Disposal Instructions

Disposal must adhere to specific pharmaceutical waste guidelines. Unused or expired Neurodiclovit must not be thrown into wastewater or household waste. To ensure environmental protection, patients should return the medicine to a pharmacist for proper disposal as dictated by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurodiclovit found in:

A-Z Index: